» Articles » PMID: 16156677

Alternatives to Levodopa in the Initial Treatment of Early Parkinson's Disease

Overview
Journal Drugs Aging
Specialties Geriatrics
Pharmacology
Date 2005 Sep 15
PMID 16156677
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is primarily a disease of elderly patients. This article reviews current knowledge and recent developments relating to drugs that can be used as alternatives to levodopa as initial treatment of PD. Synthetic orally acting dopamine agonists have found increasing favour as an option for early PD in relatively young patients. This strategy is based on evidence that this approach may delay the onset of motor fluctuations, at least during the first 5 years of treatment. Subcutaneous apomorphine infusions may attenuate motor fluctuations in late-stage disease, and transdermal rotigotine, a dopamine agonist in development, has also been shown to be efficacious. The greater proclivity for dopamine agonists to cause psychotoxicity has, however, limited their routine use in the elderly. Selective monoamine oxidase type B (MAO-B) inhibitors, used as monotherapy, delay the need for the introduction of levodopa by about 9 months. These agents appear to be less efficacious than dopamine agonists but are better tolerated. Concern has been expressed about the potential of the MAO-B inhibitor selegiline (deprenyl) to induce cardiovascular adverse effects (orthostatic hypotension), either directly or through its amphetamine catabolites. Rasagiline is a new MAO-B inhibitor that is not broken down to amphetamine derivatives and is indicated as both monotherapy in early PD and as adjunctive therapy in PD patients with motor fluctuations. Two older classes of agents have undergone a resurgence of interest in recent years. Amantadine, which enhances dopaminergic transmission and has antiglutamate activity, is occasionally used as monotherapy but has recently been widely used as an antidyskinetic agent in late-stage PD. Anticholinergic drugs, such as benztropine (benzatropine) and orphenadrine also provide control of symptoms when used as monotherapy, but their psychotoxic, cognitive and autonomic adverse events make them inappropriate for the treatment of the elderly. Effective therapy in PD should prevent disease progression and abolish motor and cognitive handicap. Currently, none of the existing drugs meets all these needs.

Citing Articles

High-throughput discovery of highly selective reversible hMAO-B inhibitors based on at-line nanofractionation.

Fan Y, Wang J, Jian J, Wen Y, Li J, Tian H Acta Pharm Sin B. 2024; 14(4):1772-1786.

PMID: 38572096 PMC: 10985270. DOI: 10.1016/j.apsb.2024.01.020.


A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [I]I-FP-CIT SPECT in routine practice.

Chahid Y, Sheikh Z, Mitropoulos M, Booij J Eur J Nucl Med Mol Imaging. 2023; 50(7):1974-1987.

PMID: 36847827 PMC: 10199883. DOI: 10.1007/s00259-023-06171-x.


Bilirubin: A Promising Therapy for Parkinson's Disease.

Jayanti S, Moretti R, Tiribelli C, Gazzin S Int J Mol Sci. 2021; 22(12).

PMID: 34207581 PMC: 8228391. DOI: 10.3390/ijms22126223.


Striatal Dopamine D-Muscarinic Acetylcholine M Receptor-Receptor Interaction in a Model of Movement Disorders.

Crans R, Wouters E, Valle-Leon M, Taura J, Massari C, Fernandez-Duenas V Front Pharmacol. 2020; 11:194.

PMID: 32231561 PMC: 7083216. DOI: 10.3389/fphar.2020.00194.


Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Latt M, Lewis S, Zekry O, Fung V Drugs Aging. 2019; 36(3):189-202.

PMID: 30623310 DOI: 10.1007/s40266-018-0629-0.


References
1.
Whone A, Watts R, Stoessl A, Davis M, Reske S, Nahmias C . Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003; 54(1):93-101. DOI: 10.1002/ana.10609. View

2.
Ives N, Stowe R, Marro J, Counsell C, MacLeod A, Clarke C . Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. 2004; 329(7466):593. PMC: 516655. DOI: 10.1136/bmj.38184.606169.AE. View

3.
Pfeiffer R . Potential of transdermal drug delivery in Parkinson's disease. Drugs Aging. 2002; 19(8):561-70. DOI: 10.2165/00002512-200219080-00002. View

4.
Lees A, Katzenschlager R, Head J, Ben-Shlomo Y . Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. 2001; 57(9):1687-94. DOI: 10.1212/wnl.57.9.1687. View

5.
. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12):1937-43. DOI: 10.1001/archneur.59.12.1937. View